Tumor Profiling Market Size & Growth Forecast 2026–2035, By Segments (Technique), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Tumor Profiling Market size was assessed at USD 12.99 Billion in 2025 and is poised to grow at a 10.2% CAGR between 2026 and 2035, reaching USD 34.31 Billion by 2035. The industry revenue for 2026 is calculated at USD 14.17 billion.

• Base Year Value (2025): USD 12.99 Billion
• CAGR (2026-2035): 10.2%
• Forecast Year Value (2035): USD 34.31 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Tumor Profiling Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held a 38.90% market share in 2025, driven by advanced oncology diagnostics infrastructure, broad genomic testing availability, and strong integration of molecular profiling into clinical care.
  • Asia Pacific is expected to expand at an 11.42% CAGR as molecular testing access improves, laboratory capabilities expand, and profiling becomes more widely used for cancer diagnosis and treatment planning.

• Segment Momentum:

  • Genomics leads with a 40.28% share because it identifies tumor mutations and directly supports targeted therapy decisions, making it central to established oncology diagnostic workflows.
  • Epigenetics is gaining momentum as it reveals gene regulation and tumor heterogeneity insights beyond genomics, supporting deeper biological understanding in advanced profiling applications.

• Market Expansion Drivers:

  • Rising cancer incidence driving demand for precision oncology-based personalized treatment selection.
  • Next-generation sequencing advancements enabling faster, more accurate genomic tumor analysis.
  • Expansion of AI-driven bioinformatics platforms improving tumor data interpretation and clinical workflows.

• Leading Market Participants:

  Major companies in the tumor profiling market include Illumina, Inc. (United States), QIAGEN N.V. (Netherlands), Exact Sciences Corporation (United States), Guardant Health, Inc. (United States), Foundation Medicine, Inc. (United States), NeoGenomics, Inc. (United States), Bruker Corporation (United States), Veracyte, Inc. (United States), Thermo Fisher Scientific Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 12.99 Billion
  • 2026 Market Size: USD 15.2 billion
  • Projected Market Size: USD 34.31 Billion by 2035
  • Growth Forecasts: 10.2% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Genomics (Technique)
  • Emerging Opportunity Segment: Epigenetics (Technique)

Market Growth Drivers and Industry Trends

Rising cancer incidence driving demand for precision oncology-based personalized treatment selection

As cancer diagnoses increase, treatment pathways are becoming more dependent on molecular characterization rather than tumor site alone, which is driving demand for the tumor profiling market. Oncologists and cancer centers are using profiling results to identify actionable mutations, stratify patients for targeted therapies, and avoid ineffective regimens that add cost and toxicity without improving outcomes. This trend makes tumor profiling a more routine step in clinical decision-making, especially in cases where therapy selection, resistance monitoring, or eligibility for biomarker-linked treatments depends on genomic and proteomic evidence.

Next-generation sequencing advancements enabling faster, more accurate genomic tumor analysis

Improved next-generation sequencing workflows are reducing turnaround times while expanding the number and quality of detectable alterations, strengthening market development in the tumor profiling market. Higher sensitivity and broader panel coverage allow laboratories to detect clinically relevant mutations, fusions, copy number changes, and other biomarkers from limited tissue samples, which is critical in oncology settings where biopsy material is often scarce. As testing becomes more reliable and operationally efficient, hospitals, diagnostic labs, and oncology networks are more willing to integrate comprehensive profiling into standard care pathways rather than reserving it for complex or late-stage cases.

Expansion of AI-driven bioinformatics platforms improving tumor data interpretation and clinical workflows

The expansion of AI-driven bioinformatics platforms is influencing market adoption by turning complex sequencing output into clinically usable insights at a scale that manual interpretation cannot match. In the tumor profiling market, these platforms help prioritize variants, connect findings to therapy options and trial matching, and reduce the reporting burden on molecular pathologists and oncology teams. That practical improvement in workflow efficiency is especially important as test volumes rise and biomarker panels become more complex, making AI-enabled interpretation a key factor supporting broader use of tumor profiling in routine cancer care.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising cancer incidence driving demand for precision oncology-based personalized treatment selection	2.20%	High	North America, Europe	High	Near Term
Next-generation sequencing advancements enabling faster, more accurate genomic tumor analysis	2.00%	High	North America, Asia Pacific	High	Near Term
Expansion of AI-driven bioinformatics platforms improving tumor data interpretation and clinical workflows	1.60%	Moderate	Asia Pacific, North America	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 38.90% share of the tumor profiling market in 2025, supported by the region’s established oncology diagnostics infrastructure, broad availability of advanced genomic testing platforms, and high integration of molecular profiling into routine cancer care. Market leadership is reinforced by the practical use of tumor profiling across hospitals, specialty cancer centers, and reference laboratories, where testing is increasingly embedded in treatment selection, biomarker identification, and clinical decision-making. The region’s position is also supported by strong adoption of precision medicine workflows and the presence of companies actively commercializing profiling technologies across research and clinical settings.

Asia Pacific is projected to expand at an 11.42% CAGR over the forecast period, with the tumor profiling market gaining momentum as cancer diagnostics capacity broadens and access to molecular testing improves across major healthcare systems. Growth is being impelled by rising use of genomic and companion diagnostic approaches in oncology practice, alongside increasing deployment of advanced laboratory capabilities in urban and high-volume care centers. As regional providers continue incorporating profiling tools into cancer detection and therapy planning pathways, adoption is accelerating in ways that directly support higher test volumes and wider clinical use.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Nascent
Cost-Sensitive Region	Medium	High	Medium	High	High
Regulatory Environment	Supportive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Moderate	Strong	Moderate	Weak
Development Stage	Developed	Developing	Developed	Developing	Emerging
Adoption Rate	High	Medium	High	Medium	Low
New Entrants / Startups	Moderate	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Stable	Stable	Weak	Weak

Key Country Insights

United States

Precision Oncology Expansion

The U.S. tumor profiling market continues to expand through wider adoption of genomic testing in personalized cancer treatment. Healthcare providers increasingly integrate comprehensive molecular profiling into clinical decision-making and targeted therapy selection.

Japan

Clinical Genomics Adoption

Japan is strengthening tumor profiling through greater integration of molecular diagnostics into oncology practice. Healthcare institutions prioritize accurate biomarker identification that supports individualized treatment planning and improved clinical decision processes.

South Korea

Advanced Cancer Testing

South Korea continues expanding tumor profiling capabilities through investment in precision medicine and advanced laboratory infrastructure. Providers increasingly adopt next-generation sequencing platforms to improve personalized oncology care and biomarker-driven treatment selection.

Germany

Molecular Diagnostics Integration

Germany emphasizes tumor profiling as part of precision oncology programs within hospitals and specialized diagnostic laboratories. Clinical adoption is supported by demand for standardized testing workflows and high-quality genomic analysis capabilities.

France

Personalized Treatment Support

France is advancing tumor profiling by incorporating comprehensive molecular testing into multidisciplinary cancer care pathways. Clinical stakeholders focus on improving access to biomarker analysis that guides targeted therapeutic decisions across oncology specialties.

Italy

Oncology Diagnostics Development

Italy is expanding tumor profiling services through collaboration between hospitals, research institutions, and diagnostic laboratories. Healthcare providers increasingly rely on molecular profiling to strengthen personalized cancer treatment strategies and clinical evaluation.

Segment Leadership and Growth Trends

  Technique Segment Analysis: Genomics (Largest Segment) vs Epigenetics (Fastest-Growing Segment)

Within the tumor profiling market, Genomics held a 40.28% share in 2025, making it the leading technique segment. This leadership is maintained through the central role of genomic analysis in identifying tumor-specific mutations, guiding targeted therapy selection, and supporting routine oncology decision-making. Genomics remains deeply embedded in tumor profiling workflows because it provides directly actionable molecular information that clinicians and laboratories can integrate into established diagnostic and treatment pathways.

Epigenetics is emerging as the fastest-growing technique in the tumor profiling market as demand rises for deeper insight beyond sequence-level alterations. Its momentum is being backed by the growing need to understand gene regulation, tumor heterogeneity, and disease progression patterns that may not be fully captured through genomics alone. Compared with more established techniques, epigenetics is gaining traction because it helps expand the biological context of tumor assessment, making it increasingly relevant for advanced profiling applications.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Technique	Genomics, Proteomics, Metabolomics, Epigenetics	Genomics	Epigenetics

Competitive Landscape and Market Positioning

Top players in the tumor profiling market:

1. Illumina Inc. (United States)

2. QIAGEN N.V. (Netherlands)

3. Exact Sciences Corporation (United States)

4. Guardant Health Inc. (United States)

5. Foundation Medicine Inc. (United States)

6. NeoGenomics Inc. (United States)

7. Bruker Corporation (United States)

8. Veracyte Inc. (United States)

9. Thermo Fisher Scientific Inc. (United States)

10. F. Hoffmann-La Roche Ltd (Switzerland)

Advancements in precision diagnostics are accelerating transformation in the tumor profiling market, enabling more targeted clinical decision-making. Integration of genomic and molecular analytics is improving diagnostic accuracy and treatment alignment. Collaborative frameworks across research and clinical ecosystems are enhancing innovation speed. The tumor profiling market is increasingly defined by the shift toward highly personalized oncology insights.

Industry Development/News

Company Name	Date	Key Development
ClearNote Health	Sep-25	ClearNote Health secured $52 million in Series D financing to accelerate the commercialization of its noninvasive early cancer detection technologies. This capital infusion, combined with leadership expansion, strengthens the company’s ability to scale operations and meet the rising demand for advanced oncology diagnostics within the tumor profiling landscape.
Cartography Biosciences	Sep-25	Cartography Biosciences received a strategic investment from Samsung Ventures to bolster its proprietary drug discovery platform and oncology pipeline. This partnership enhances the company’s capabilities in precision medicine by integrating advanced computational approaches with tumor profiling, supporting the development of highly targeted oncology solutions.
Illumina	Aug-25	Illumina expanded its precision oncology partnership with Labcorp to co-develop and commercialize distributed NGS-based in vitro diagnostic tests. By combining their respective liquid and tissue biopsy expertise, the firms aim to increase market access to comprehensive cancer biomarker testing and standardized tumor profiling workflows.
Genomate Health	Aug-25	Genomate Health acquired Oncompass Medicine to establish an expanded operational footprint in Europe and strengthen its global position. The integration of Oncompass’s precision medicine assets enhances Genomate’s computational oncology capabilities, facilitating more robust data-driven insights for personalized cancer care and tumor profiling applications.
Elephas Biosciences	Aug-25	Elephas Biosciences raised $40 million in Series B-2 financing to support the commercialization of its live tumor profiling platform. The funding will be utilized to finalize launch preparations for its laboratory-developed test, which evaluates real-time patient response to immunotherapy, representing a material advancement in functional precision oncology.
Thermo Fisher Scientific	Aug-25	Thermo Fisher Scientific received FDA approval for the Oncomine Dx Express Test, an NGS-based assay that serves as a companion diagnostic for sunvozertinib in non-small cell lung cancer. This regulatory milestone bolsters the company’s competitive position by providing a streamlined, rapid profiling solution for clinical precision oncology.
Pleno	Aug-25	Pleno raised $25 million to advance the commercialization of its multiomics platform and the upcoming launch of the Raptor benchtop analyzer. This investment enhances the company’s ability to scale advanced molecular analysis technologies, providing a scalable infrastructure for high-throughput tumor profiling and complex genomic research.
Pillar Biosciences	Aug-25	Pillar Biosciences launched oncoReveal Lymphoid, an NGS-based assay designed for the rapid profiling of lymphoid malignancies. This addition to the company’s oncology portfolio provides molecular laboratories with a targeted diagnostic tool, addressing specific clinical needs in hematologic oncology and expanding the firm's reach in clinical testing markets.
Illumina	Aug-24	Illumina received FDA approval for the TruSight Oncology Comprehensive, an in vitro diagnostic kit assessing over 500 genes. This tool provides critical pan-cancer companion diagnostic claims, significantly improving clinical capabilities for patient stratification and therapeutic matching through comprehensive genomic profiling.
QIAGEN	Jun-22	QIAGEN launched the therascreen EGFR Plus RGQ PCR Kit to detect the C797S mutation in non-small cell lung cancer patients. By enabling the identification of specific resistance mutations via real-time PCR, the kit provides essential insights for therapy selection, demonstrating the company’s focus on advancing personalized oncology care.